Cargando…
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
With drug approval times taking an average of 8 years from entry into clinical trials to full U.S. Food and Drug Administration (FDA) approval, patients with life-threatening and severely debilitating disease and no reasonable therapeutic options are advocating for expanded access (EA) to investigat...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059004/ https://www.ncbi.nlm.nih.gov/pubmed/30062214 http://dx.doi.org/10.1016/j.jacbts.2017.11.007 |